A review on role of ATM gene in hereditary transfer of colorectal cancer

Sushmitha Sriramulu1, Murugesan Ramachandran1, Saraswathi Subramanian1, Rathiusha Kannan1, Madhumala Gopinath1, Jose Sollano3, Laura Bissi2, Antara Banerjee1, Francesco Marotta2, Surajit Pathak1

1 Department of Allied Health Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Chennai-603103, India; 2 ReGenera R&D International for Aging Intervention, Milano-Beijing, Italy-China, VCC Preventive Medical Promotion Foundation, Beijing, China; 3 Gastroenterology Department, University of Santo Tomas, Manila, the Philippines

Summary. Colorectal cancer found to be the most commonly occurring cancer worldwide which can be prevented by screening and its curable if diagnosed early. Lynch syndrome/HNPCC being an autosomal genetic disease and propensity in forming colorectal cancer is inherited wherein genomic instabilities and epigenetic changes are being the characteristic forms in hereditary cancers. It is very important to determine the polymorphism in several DNA repairing genes such as ATM, RAD51, XRCC2, XRCC3 and XRCC9 to study the risk exploring both the prognosis and the developing of colorectal cancer. The role of ATM gene has been studied which involves in the hereditary transfer of colorectal cancer associated with other related cancers such as stomach, lung and breast cancers. ATM found to be the mutation target and also a modifier gene with more risk of developing the disease by its polymorphism in variant of ATM D1853N. It was identified that ATM gene polymorphism did not drastically change HNPCC age of onset. ATM expression levels were studied and it has been concluded that the complete loss of ATM expression resulted in a propensity of worse survival and no better prognosis with increase in mortality rate. This ATM gene might be considered to be a predicted biomarker in colorectal cancer. (www.actabiomedica.it)

Key words: ataxia-telangiectasia mutated, colorectal cancer, epigenetic change, lynch syndrome, polymorphism

Introduction

Colorectal cancer is found to be the fourth commonly occurring cancer worldwide (1, 2). It usually occurs from a pre-cancerous growth called a polyp in a very predictable way. It has been recognized that the ceaseless assembly of activation of oncogene and deactivation of tumor suppressor genes is primarily linked with the advancement of colorectal adenoma to cancer where the genes located on small arm of the chromosome 17 and large arm of the chromosome 18 which plays a significant part in the advancement of colon cancer (3). The primary alteration of genetic and epigenetic occurs that in succession promotes the colon cancer formation as they provide clonal expansion or clonal growth advantage to the cell. Thus, this cancer starts via a numerous step progression at both molecular level and morphological extent leading to the loss of genomic stability which is a primary molecular step in cancer emergence. Finally, hereditary cancer syndromes often tend to the germ line arrangement of key genetic flaws, which trigger the appearance of infrequent colon cancers. It is now widely accepted that the different types of genomic instability may result in
distinct molecular pathways of carcinogenesis (33, 34). Three forms of genetic uncertainty in colorectal cancer have been reported (4). In 13% of colorectal cancer case studies, mismatch repair insufficiency tends to microsatellite instability. Around 40% colorectal cancer tumors are distinguished by epigenetic modifications mainly DNA methylation; an event known as CpG Islands Methylator Phenotype (CIMP). CIMP is more often detected in tumors with proximal location, microsatellite instability. About 15% of microsatellite instability is detected in colon cancer where 3% of these are linked to Lynch syndrome and the remaining 12% caused by sporadic, which has promoter hypermethylation of MLH1 gene occurring in the malignancy with the CpG island methylator phenotype but the part of this hypermethylation in previous stage of colorectal carcinogenesis, specifically in adenomas and non-cancer tissues of cancer patients, is not that well explained (5-7). In the last 47% of colorectal cancer, chromosomal uncertainty escort to gains and losses of large segments of chromosomes. This chromosomal instability leads to a pattern of gene alterations which culminates in tumor formation (8). All cancers are inherited of about 5-10% having the most in an autosomal dominant way with deficient penetrance (9). Ataxia-telangiectasia mutated gene was identified to change the phenotypic expression/pronouncement of HNPCC. This gene was linked with notably increased occurrence of colon and other HNPCC-related cancers (10). Germ-line ATM mutations will not display the exact phenotype of the disease but are examined at more risk of developing epithelial tumors, such as breast and stomach cancers. The feasible involvement of ATM in a wide diversity of human solid cancers has also been recommended. Allelic loss studies have stipulated that the chromosome 11q22.3 region, comprising the ATM locus, is often modified in many cancers, such as cancers of the breast, colon, lung, cervix and in neuroblastoma. ATM is considered to be a mutation target of microsatellite instability where abnormal transcripts are originated indirectly by intron mutations (11). Promoter hypermethylation were often recognized in more than 40% of colonic cancers and adenomas in APC, ATM, MGMT, HLTF, hMLH1 genes which was found to be more prone in older patients (12) (Fig. 1).

**Figure 1.** Promoter hypermethylation recognized in colon cancers-following genes

**Literature review**

A study involving 167 Swiss individuals from around 20 HNPCC families was reported by P. Maillet et al. (2000), analyzed the genomic DNA from peripheral lymphocytes wherein 120 (72%) individuals were without symptoms and 47 (28%) was progressed with cancer. Among them 67 are MLH1 or MSH2 mutation carriers, the ATM1853N variant/mutant was found to be linked with a relatively increased emergence of colon and other HNPCC-related cancers, when compared with patients bearing the ATM1853D variant. In 2004, Wai K. Leung et al. analyzed the epigenetic transformations in fecal DNA of individuals with colorectal cancer of age ranging from 45-90 years as a molecular screening test. They examined the possibility of identifying promoter hyper-methylation of many tumor-type genes. The methyl-DNA located in colon tissues and stool was also identified by methyl-specific PCR. Deborah Thompson et al., in 2005 studied the likelihood of cancer in heterozygous ATM mutation carriers by using lymphoblastoid cell lines took from blood samples in 1160 relatives of 169 UK A-T patients comprising 247 obligate carriers obtained from the National Health Service Central Registry and were detected by genotyping; western blotting, PCR and statistical tests were carried out. The likeli-
The most common genetic syndrome with elevated rates of colorectal cancer is the hereditary nonpolyposis colorectal cancer (HNPCC/Lynch syndrome) normally triggered by inherited mutations in one of five DNA mismatch repair (MMR) genes found in 3% of people with colon cancer (17). The mutation in DNA repair genes results in genomic instability in hereditary cancers and triggers the cancer development (18). Genomic instabilities that have been detected in colon cancer are microsatellite instability and as well as chromosome instability (19). HNPCC patients with tumors produce as adenomas and often modify to carcinoma. Ovarian, endometrial, urin ary tract, gastric cancer and biliary tract are also characteristics of this syndrome and are identified more often in families with HNPCC which is suspected to account imprecisely 1% to 5% of all colorectal cancers and 0.5% to 1.4% of all endometrial cancers (20, 21). Ataxiatelangiectasia mutated gene (ATM gene) was found to be an interesting candidate as a remodeling gene in HNPCC where ATM 1853N variant having 8 times higher chance of forming a HNPCC-related cancer comparable with a MLH1 or MSH2 mutation carrier with the ATM 1853D variant in HNPCC patients. So this suggests that ATM 1853N plays a notable part in changing the penetrance of germ-line mutations (22). The sequence alteration resulted in intronic mononucleotide tract shortening preceding some of the ATM exons in colon tumor cell lines with microsatellite uncertainty followed by decreased depression in the level of ATM protein (18). From the studies of P. Maill et al. (2000), it has been found that MLH1 and MSH2 mutation carriers with the ATM1853N variant had an 8 times higher chance of forming colorectal when comparable with MLH1 or MSH2 mutation carriers with the ATM1853D variant. This study suggests that the ATM D1853N polymorphism regulates MLH1 and MSH2 germ-line mutations. Six tumor-related genes was examined by Wai K. Leung et al. (2004), which includes APC, ATM, HJLF, MGMT and bMLH1. Promoter hyper-methylation was also often detected in colorectal cancer such as ATM (45%), APC (55%), bMLH1 (45%), MGMT (45%) and HJLF (50%). (Fig. 3) To conclude, the samples had promoter hypermethylation identified in one of the five tumor-related genes. According to Deborah Thompson et al. (2005), the carriers of mutations encoded a complete-length ATM protein had cancer risks alike to those of people
carrying truncated mutations. These results in average risk of breast cancer in A-T heterozygotes and provide chance of more risk of other cancers. Alfa H.C. Bai et al. (2004), who inspected the promoter hyper methylation in 10 tumor-type genes by methyl specific PCR concluded that there was no link between promoter hyper-methylation and other clinico-pathologic properties of cancer. Studies of Yosuke Ejima et al. (2000), indicated that ATM is a mutation target of microsatellite instability where aberrant transcripts were produced indirectly by intron mutations, which was found to be distinct and the exonic repeats were directly affected (Fig. 2).

Alterations of ATM are proposed to be susceptible in specific to lymphoproliferative syndromes (24). ATM allelic imbalance exhibited a high frequency in multiploid carcinomas in chromosome 11q22-23 when compared with diploid and aneuploidy carcinomas (25). The overall relative cancer risk was found to be higher for both gender carriers younger than 50 years of age, with minute proof of more risk for carriers aged around 50 years and also elder (14).
Other related cancers

In a study, ATM genotype showed link with lung cancer risk which suggests that polymorphisms of ATM plays a part in the progression of lung cancer (26). It has been initiated that ATM mutation heterozygotes had double fold more breast cancer chance comparable to the normal population. This likelihood was upgraded 5-fold in women with below age of 50 (27). ATM mutations of homozygous or heterozygous type cause ataxia and were recognized by progressive cerebellar ataxia, oculomotor apraxia, immunodeficiency, and increased chance of tumors (28). Epithelial cancers, lymphoid cancers primarily in childhood, breast cancer are seen normally in adults (29). There is an increased evidence for an complete chance of cancers other than breast cancer in ATM heterozygotes such as colorectal cancer and stomach cancer of clear higher mortality from cancer with statistically specific excess risks of colorectal and lung cancer deaths. There is a possible link between ATM and cancers of the gastrointestinal tract which was found to be statistically significant (30). It was found that the ATM variations may also modify the chance of neoplasia in breast and in digestive epithelia. ATM plays a very active role when exposed to tobacco smoke which induces expression of ATM in oesophageal cancer cell lines (31).

Conclusion

ATM is known to be the newer risk gene where the heterozygous carriers of ATM mutations are at higher chance of cancers and a major form of genetic instabilities. This study suggests that the variant of ATM D1853N polymorphism is linked with the more risk of developing a HNPCC-related cancer which remains to be highly significant (10) evidence of link between a single non-conservative point mutation in ATM and expression of phenotype in HNPCC (32) (Fig. 4). This study concludes that the occurrence of cancer in MLH1 or MSH2 mutation carriers is by the existence of a specific ATM polymorphism. The level of ATM protein expression in colon cancer cell lines was

Figure 4. Genomic instability & DNA damage (ATM mutation)
found to be three fold significantly different from that of breast cell lines (33). Decreased ATM expression is linked to indigent survival in patients with CRC (34). Loss of ATM expression resulted in a tendency towards the worse survival in colorectal cancer poorer prognosis in colorectal cancers associated with chromosomal instability (15). Link between the ATM genotypes and HNPCC age onset of survival analysis resulted that the ATM polymorphism did not transform HNPCC age of onset (35). As mismatch repair defects did not account for the majority of colorectal cancers, ATM was found to be attractive candidate gene for the inactivation and in the progress of chromosomal instability in tumor cells (36). The HNPCC condition in colorectal cancer varies from sporadic colorectal cancer in many ways where the moderate age onset is 45 years, it was found to be 63 years in the normal population. Thereby the mortality rate in ATM carriers was found to be high with the stomach and colorectal cancer of below 50 years of age (37, 38). There are many possible modifiers which includes loci encoded xenobiotic enzymes NAT1, GSTM1, NAT2, GSTT1 (7-9), MTHFR gene which results in changes in these loci further modulating the age onset, penetrance and position of cancer in MLH1 & MSH2 mutation carriers. Thus, this ATM gene might be considered as a prognostic biomarker in colorectal cancer; however the association between ATM gene and hereditary transfer of colorectal cancer still remains controversial.

Acknowledgments

The authors are thankful to Chettinad Academy of Research and Education (CARE), Chennai, India.

Funding Sources:
This study was financially supported by grants Chettinad Academy of Research and Education, Chennai, India.

References


Received: 5 January 2017
Accepted: 30 January 2018
Correspondence:
Surajit Pathak,
Chettinad Hospital and Research Institute (CHRI),
Chettinad Academy of Research and Education (CARE),
Kelambakkam, Chennai-603103, India
E-mail: surajit.pathak@gmail.com